Senestech, INC 10-Q quarterly reports

SenesTech, Inc. reported a 43% increase in third-quarter revenue, driven by strong adoption of its Evolve fertility control products, and announced that it has alleviated substantial doubt about its ability to continue as a going concern.

SenesTech, Inc. reported a 36% increase in net revenue for Q2 2025, driven by strong adoption of its Evolve product line, while reducing its net loss.

SenesTech, Inc. reports a 17% increase in net revenue for the first quarter of 2025, driven by the success of its Evolve product line, while still facing operating losses and a need for additional financing.

SenesTech's Q3 2024 results show a significant revenue increase driven by the launch of their new Evolve product line, despite ongoing operating losses.

SenesTech's Q2 2024 results show a significant revenue increase driven by the launch of new products, Evolve and Evolve Mouse, despite ongoing operating losses.

SenesTech's first quarter 2024 results show a significant increase in revenue compared to the same period last year, primarily driven by the launch of their new product, Evolve.